Lung Cancer Clinical Trials

Showing 381-400 of 2,032 trials

RECRUITING

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

NCT07143513

The primary objective of this study is to characterize the safety profile of sotorasib.

Non-Small Cell Lung Cancer

Amgen115 participantsStarted Aug 2025

Qionghai, Hainan, China • Qionghai, Hainan, China • Qionghai, Hainan, China

COMPLETEDPHASE4

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

NCT05219162

Although some small sample studies have reported the possible resistance mechanisms of Osimertinib in the first-line treatment, it is still an urgent need to explore the whole gene profile in EGFRm advanced NSCLC patients post Osimertinib 1L treatment by paired tissue and plasma to guide subsequent treatment strategy. Thus, the gene profile post Osimertinib 1L treatment in tissue and plasma may help to guide the following treatment. Participants will be required to provide paired tissue and whole blood after disease progression following 1L Osimertinib. 200 tissue samples and 200 whole blood samples will be used to detect gene alteration by NGS, respectively. 200 tissue samples will be used to detect pathological transformation by IHC. Approximately 80-100 tissue samples will be used to test MET overexpression by MET IHC and MET amplification by FISH respectively. Approximately 80-100 whole blood samples will be used to test MET amplification by ddPCR.

Advanced NSCLC

AstraZeneca182 participantsStarted Feb 2022

Beijing, China • Changsha, China • Chengdu, China +13 more locations

Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Related Searches

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

Immune-Marker Platform for Patients With Advanced Lung Cancer

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Safety and Efficacy of Lorbrena

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung Cancer

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation